Abstract:Objective To investigate the effect of smeglutide combined with metformin on patients with type 2 diabetes mellitus (T2DM) and abdominal obesity.Methods A total of 98 patients with T2DM and abdominal obesity treated in Puyang People's Hospital from August 2022 to August 2024 were randomly divided into two groups, with 49 cases in each group. The control group was treated with metformin, and the observation group was treated with smeglutide and metformin. After 12 weeks of treatment, islet function, glucose metabolism indexes, body mass index (BMI), and adverse reactions were compared between the two groups.Results Compared with before treatment, both groups showed a decrease in fasting insulin (FINS), fasting C-peptide (FC-P), insulin resistance index (HOMA-IR), fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycated hemoglobin (HbA1c), and BMI after treatment, and data of the observation group were lower than those of the control group, After treatment, the insulin secretion index (HOMA-β) of the two groups were increased, and data of the observation group were higher than that of the control group, with statistically significant (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The application of smeglutide combined with metformin in patients with T2DM and abdominal obesity can help improve islet function and glucose metabolism indicators, manage body weight, and has good safety.